Search Results - "Watts, Justin M."

Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development by Stanchina, Michele, Soong, Deborah, Zheng-Lin, Binbin, Watts, Justin M, Taylor, Justin

“…Acute myeloid leukemia (AML) is a genetically heterogeneous malignancy comprised of various cytogenetic and molecular abnormalities that has notoriously been…”
Get full text

KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study by Swords, Ronan T., MD, PhD, FRCPI, FRCPath, Greenberg, Peter L., MD, Wei, Andrew H., MBBS, PhD, Durrant, Simon, MBBS, MRCS, LRCP, FRCP, FRCPath, Advani, Anjali S., MD, Hertzberg, Mark S., MBBS, PhD, FRACP, FRCPA, Lewis, Ian D., MBBS, PhD, Rivera, Gabriel, MD, Gratzinger, Dita, MD, PhD, Fan, Alice C., MD, Felsher, Dean W., MD, PhD, Cortes, Jorge E., MD, Watts, Justin M., MD, Yarranton, Geoff T., PhD, Walling, Jackie M., MB, ChB, PhD, Lancet, Jeffrey E., MD

“…Highlights • KB004 is a novel anti-ephrin novel monoclonal antibody targeting EphA3. • KB004 was safe and relatively well-tolerated in patients with myeloid…”
Get full text

A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy by Watts, Justin M, Perez, Aymee, Pereira, Lutecia, Fan, Yao-Shan, Brown, Geoffrey, Vega, Francisco, Petrie, Kevin, Swords, Ronan T, Zelent, Arthur

“…Here we report the case of a 30-year-old woman with relapsed acute myeloid leukemia (AML) who was treated with all- retinoic acid (ATRA) as part of…”
Get full text

Telomere Length and Associations with Somatic Mutations and Clinical Outcomes in Acute Myeloid Leukemia by Watts, Justin M., MD, Dumitriu, Bogdan, MD, Hilden, Patrick, MS, Kishtagari, Ashwin, MD, Rapaport, Franck, PhD, Chen, Christina, BS, Ahn, Jihae, Devlin, Sean M., PhD, Stein, Eytan M., MD, Rampal, Raajit, Levine, Ross L., MD, Young, Neal, MD, Tallman, Martin S., MD

“…Highlights • Telomere length (TL) may be associated with clinical outcomes in AML. • TL in AML appears to be associated with mutational class (i.e. activating…”
Get full text

The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia by Watts, Justin M, Bradley, Terrence

“…Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared…”
Get full text

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia by Roboz, Gail J., DiNardo, Courtney D., Stein, Eytan M., de Botton, Stéphane, Mims, Alice S., Prince, Gabrielle T., Altman, Jessica K., Arellano, Martha L., Donnellan, Will, Erba, Harry P., Mannis, Gabriel N., Pollyea, Daniel A., Stein, Anthony S., Uy, Geoffrey L., Watts, Justin M., Fathi, Amir T., Kantarjian, Hagop M., Tallman, Martin S., Choe, Sung, Dai, David, Fan, Bin, Wang, Hongfang, Zhang, Vickie, Yen, Katharine E., Kapsalis, Stephanie M., Hickman, Denice, Liu, Hua, Agresta, Samuel V., Wu, Bin, Attar, Eyal C., Stone, Richard M.

“…Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate…”
Get full text

Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729] by Swords, Ronan T., MD, PhD, Greenberg, Peter L., MD, Wei, Andrew H., MBBS, PhD, Durrant, Simon, MBBS, Advani, Anjali S., MD, Hertzberg, Mark S., MBBS, PhD, Lewis, Ian D., MBBS, PhD, Rivera, Gabriel, MD, Gratzinger, Dita, MD, PhD, Fan, Alice C., MD, Felsher, Dean W., MD, PhD, Cortes, Jorge E., MD, Watts, Justin M., MD, Yarranton, Geoff T., PhD, Walling, Jackie M., MB, ChB, PhD, Lancet, Jeffrey E., MD

Get full text

Acute promyelocytic leukemia: What is the new standard of care? by Watts, Justin M, Tallman, Martin S

“…Abstract Acute promyelocytic leukemia (APL) is one of the most exciting stories of modern medicine. Once a disease that was highly lethal, the majority of…”
Get full text

Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia by Watts, Justin M., Shaw, Simon J., Jonas, Brian A.

“…Opinion Statement Mutations in isocitrate dehydrogenase-1 ( IDH1) are recurrent in several malignancies and prevalent in acute myeloid leukemia (AML)…”
Get full text

Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies by Tayari, Mina M, Santos, Helena G Dos, Kwon, Deukwoo, Bradley, Terrence J, Thomassen, Amber, Chen, Charles, Dinh, Yvonne, Perez, Aymee, Zelent, Arthur, Morey, Lluis, Cimmino, Luisa, Shiekhattar, Ramin, Swords, Ronan T, Watts, Justin M

“…In preclinical studies, the lysine-specific histone demethylase 1A (LSD1) inhibitor tranylcypromine (TCP) combined with all-trans retinoic acid (ATRA) induces…”
Get full text

Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial by Gangat, Naseema, Marinaccio, Christian, Swords, Ronan, Watts, Justin M, Gurbuxani, Sandeep, Rademaker, Alfred, Fought, Angela J, Frankfurt, Olga, Altman, Jessica K, Wen, Qiang Jeremy, Farnoud, Noushin, Famulare, Christopher A, Patel, Akshar, Tapia, Roberto, Vallapureddy, Rangit R, Barath, Stephanie, Graf, Amy, Handlogten, Amy, Zblewski, Darci, Patnaik, Mrinal M, Al-Kali, Aref, Dinh, Yvonne Trang, Englund Prahl, Kristen, Patel, Shradha, Nobrega, Juan Carlos, Tejera, Dalissa, Thomassen, Amber, Gao, Juehua, Ji, Peng, Rampal, Raajit K, Giles, Francis J, Tefferi, Ayalew, Stein, Brady, Crispino, John D

“…Myelofibrosis is characterized by bone marrow fibrosis, atypical megakaryocytes, splenomegaly, constitutional symptoms, thrombotic and hemorrhagic…”
Get full text

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML by Choe, Sung, Wang, Hongfang, DiNardo, Courtney D., Stein, Eytan M., de Botton, Stéphane, Roboz, Gail J., Altman, Jessica K., Mims, Alice S., Watts, Justin M., Pollyea, Daniel A., Fathi, Amir T., Tallman, Martin S., Kantarjian, Hagop M., Stone, Richard M., Quek, Lynn, Konteatis, Zenon, Dang, Lenny, Nicolay, Brandon, Nejad, Parham, Liu, Guowen, Zhang, Vickie, Liu, Hua, Goldwasser, Meredith, Liu, Wei, Marks, Kevin, Bowden, Chris, Biller, Scott A., Attar, Eyal C., Wu, Bin

“…Isocitrate dehydrogenase (IDH) 1 and 2 mutations result in overproduction of D-2-hydroxyglutarate (2-HG) and impaired cellular differentiation. Ivosidenib, a…”
Get full text

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial by Watts, Justin M, Baer, Maria R, Yang, Jay, Prebet, Thomas, Lee, Sangmin, Schiller, Gary J, Dinner, Shira N, Pigneux, Arnaud, Montesinos, Pau, Wang, Eunice S, Seiter, Karen P, Wei, Andrew H, De Botton, Stephane, Arnan, Montserrat, Donnellan, Will, Schwarer, Anthony P, Récher, Christian, Jonas, Brian A, Ferrell, P Brent, Marzac, Christophe, Kelly, Patrick, Sweeney, Jennifer, Forsyth, Sanjeev, Guichard, Sylvie M, Brevard, Julie, Henrick, Patrick, Mohamed, Hesham, Cortes, Jorge E

“…Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase…”
Get full text

Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations by Ball, Somedeb, Knepper, Todd C., Deutsch, Yehuda E., Samra, Wassim, Watts, Justin M., Bradley, Terrence J., Chan, Onyee, Hussaini, Mohammad Omar, Zhang, Ling, Sweet, Kendra L., Kuykendall, Andrew T., Talati, Chetasi, Padron, Eric, Komrokji, Rami S., Lancet, Jeffrey E., Sallman, David A.

“…Background Genomic landscape of extramedullary acute myeloid leukemia (EM‐AML), including myeloid sarcoma (MS) and leukemia cutis (LC), is not well…”
Get full text

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies by Taylor, Justin, Pavlick, Dean, Yoshimi, Akihide, Marcelus, Christina, Chung, Stephen S, Hechtman, Jaclyn F, Benayed, Ryma, Cocco, Emiliano, Durham, Benjamin H, Bitner, Lillian, Inoue, Daichi, Chung, Young Rock, Mullaney, Kerry, Watts, Justin M, Diamond, Eli L, Albacker, Lee A, Mughal, Tariq I, Ebata, Kevin, Tuch, Brian B, Ku, Nora, Scaltriti, Maurizio, Roshal, Mikhail, Arcila, Maria, Ali, Siraj, Hyman, David M, Park, Jae H, Abdel-Wahab, Omar

“…Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide…”
Get full text

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML) by Cortes, Jorge, Jonas, Brian A, Schiller, Gary, Mims, Alice, Roboz, Gail J, Wei, Andrew H, Montesinos, Pau, Ferrell, P Brent, Yee, Karen Wl, Fenaux, Pierre, Schwarer, Anthony, Watts, Justin M

“…Olutasidenib, a potent, selective, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, is FDA-approved for relapsed/refractory (R/R) acute myeloid…”
Get full text

Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant by DiNardo, Courtney D., Stein, Eytan M., Pigneux, Arnaud, Altman, Jessica K., Collins, Robert, Erba, Harry P., Watts, Justin M., Uy, Geoffrey L., Winkler, Thomas, Wang, Hongfang, Choe, Sung, Liu, Hua, Wu, Bin, Kapsalis, Stephanie M., Roboz, Gail J., de Botton, Stéphane

Get full text

Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study by Swords, Ronan T., Azzam, Diana, Al-Ali, Hassan, Lohse, Ines, Volmar, Claude-Henry, Watts, Justin M., Perez, Aymee, Rodriguez, Ana, Vargas, Fernando, Elias, Roy, Vega, Francisco, Zelent, Arthur, Brothers, Shaun P., Abbasi, Taher, Trent, Jonathan, Rangwala, Shaukat, Deutsch, Yehuda, Conneally, Eibhlin, Drusbosky, Leylah, Cogle, Christopher R., Wahlestedt, Claes

“…•Personalized drug treatment recommendations for refractory AML.•Ex vivo drug sensitivity screens assessed individual treatment responses.•Guided treatments…”
Get full text

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML by de Botton, Stéphane, Fenaux, Pierre, Yee, Karen, Récher, Christian, Wei, Andrew H., Montesinos, Pau, Taussig, David C., Pigneux, Arnaud, Braun, Thorsten, Curti, Antonio, Grove, Carolyn, Jonas, Brian A., Khwaja, Asim, Legrand, Ollivier, Peterlin, Pierre, Arnan, Montserrat, Blum, William, Cilloni, Daniela, Hiwase, Devendra K., Jurcic, Joseph G., Krauter, Jürgen, Thomas, Xavier, Watts, Justin M., Yang, Jay, Polyanskaya, Olga, Brevard, Julie, Sweeney, Jennifer, Barrett, Emma, Cortes, Jorge

“…•Olutasidenib induced durable remissions in patients with mIDH1 R/R AML; transfusion independence was achieved across all response groups.•The side effect…”
Get full text

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia by Uckun, Fatih M, Cogle, Christopher R, Lin, Tara L, Qazi, Sanjive, Trieu, Vuong N, Schiller, Gary, Watts, Justin M

“…Combretastatin A1 (OXi4503) is a dual-function drug with vascular disrupting and cytotoxic properties that has exhibited single-agent anti-leukemia activity in…”
Get full text